Earnings History Data for C4 Therapeutics, Inc. (CCCC) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

C4 Therapeutics, Inc.

C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. C4 Therapeutics Inc. is based in WATERTOWN, Mass.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
01-11-2023	PM		CCCC	C4 Therapeutics	74.00	-0.55	-0.65	0.00	C4 Therapeutics GAAP EPS of -$0.55, revenue of $11.1M [11/1/2023 10:14 AM]	1.30	-0.19 (-12.75%)	1.57	0.08 (5.37%)	1.23 - 10.42	827,137	810,000	5,489
C4 Therapeutics GAAP EPS of -$0.55, revenue of $11.1M [11/1/2023 10:14 AM]
08-08-2023	PM		CCCC	C4 Therapeutics	181.00	-0.73	-0.74	0.00	C4 Therapeutics GAAP EPS of -$0.73, revenue of $2.7M [8/8/2023 8:04 AM]	3.52	0.0 (0.00%)	0.0	0.0 (0.00%)	2.60 - 13.23	423,710	420,000	0
C4 Therapeutics GAAP EPS of -$0.73, revenue of $2.7M [8/8/2023 8:04 AM]
03-11-2022	PM		CCCC	C4 Therapeutics	501.00	-0.65	-0.65	0.00	C4 Therapeutics GAAP EPS of -$0.65 beats by $0.02, revenue of $6.8M misses by $2.46M [11/3/2022 9:19 AM]	9.94	0.24 (2.47%)	9.70	0.0 (0.00%)	4.84 - 48.75	166,938	310,000	9,596
C4 Therapeutics GAAP EPS of -$0.65 beats by $0.02, revenue of $6.8M misses by $2.46M [11/3/2022 9:19 AM] C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights [Nov-03-22 07:00AM] C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: Can the Stock Move Higher? [Nov-02-22 10:01AM]
04-08-2022	PM		CCCC	C4 Therapeutics	490.00	-0.56	-0.68	0.00	C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M [8/4/2022 9:08 AM]	11.72	0.78 (7.13%)	3.92	-0.40 (-9.26%)	4.84 - 51.21	203,845	280,000	51,552
C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M [8/4/2022 9:08 AM] C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights [Aug-04-22 08:00AM]
05-05-2022	PM		CCCC	C4 Therapeutics	439.00	-0.65	-0.61	0.00	C4 Therapeutics GAAP EPS of -$0.65 misses by $0.06, revenue of $7.65M misses by $0.4M [5/5/2022 9:05 AM]	8.78	-0.39 (-4.25%)	8.94	-0.23 (-2.51%)	7.51 - 51.21	502,536	954,131	15,192
C4 Therapeutics GAAP EPS of -$0.65 misses by $0.06, revenue of $7.65M misses by $0.4M [5/5/2022 9:05 AM] C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights [May-05-22 08:00AM] C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates [May-05-22 09:15AM]
24-02-2022	PM	Before the open (Feb 24)	CCCC	C4 Therapeutics	1,009	-0.31	-0.59	0.00	C4 Therapeutics GAAP EPS of -$1.82 beats by $0.27, revenue of $45.78M beats by $12.7M [2/24/2022 7:44 AM]	20.75	0.76 (3.80%)	0.0	0.0 (0.00%)	0.0 - 0.0	143,441	0	0
C4 Therapeutics GAAP EPS of -$1.82 beats by $0.27, revenue of $45.78M beats by $12.7M [2/24/2022 7:44 AM] C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights [Feb-24-22 07:00AM]
10-11-2021	AH		CCCC	C4 Therapeutics	2,180	-0.51	-0.60	0.00	C4 Therapeutics EPS beats by $0.08, beats on revenue [11/10/2021 4:42 PM]	43.03	-1.70 (-3.80%)	44.73	0.0 (0.00%)	25.43 - 51.21	122,638	200,000	6,889
C4 Therapeutics EPS beats by $0.08, beats on revenue [11/10/2021 4:42 PM] C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results [Nov-10-21 04:01PM] Why C4 Therapeutics (CCCC) Might Surprise This Earnings Season [Nov-10-21 08:34AM]
11-08-2021	AH		CCCC	C4 Therapeutics, Inc.	1,606	-0.51	-0.60	0.00	C4 Therapeutics EPS beats by $0.05, beats on revenue [8/11/2021 4:49 PM]	39.62	3.71 (10.33%)	36.50	0.59 (1.64%)	22.40 - 48.98	369,649	400,000	611
C4 Therapeutics EPS beats by $0.05, beats on revenue [8/11/2021 4:49 PM] FDA grants orphan drug status to C4 Therapeutics' multiple myeloma treatment CFT7455 [8/11/2021 4:06 PM] C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results [Aug-11-21 04:02PM] C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma [Aug-11-21 04:01PM] Is C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Shareholder Ownership Skewed Towards Insiders? [Aug-10-21 01:31AM]
13-05-2021	AH	4:05 PM ET (May 13)	CCCC	C4 Therapeutics, Inc.	1,530	-0.49	-0.63	0.00	C4 Therapeutics EPS beats by $0.14, beats on revenue [5/13/2021 5:26 PM]	34.81	0.75 (2.20%)	34.06	0.0 (0.00%)	22.40 - 48.98	305,168	260,000	1,114
C4 Therapeutics EPS beats by $0.14, beats on revenue [5/13/2021 5:26 PM] C4 Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results [May-13-21 04:01PM] C4 Therapeutics to Present at Upcoming Investor Conferences [May-12-21 07:00AM]
11-03-2021	AH		CCCC	C4 Therapeutics, Inc.	1,810	N/A	-0.51	0.00	C4 Therapeutics EPS beats by $5.25, misses on revenue [3/11/2021 5:45 PM]	44.58	3.10 (7.46%)	41.48	0.0 (0.00%)	22.40 - 48.98	174,931	212,684	617
C4 Therapeutics EPS beats by $5.25, misses on revenue [3/11/2021 5:45 PM] C4 Therapeutics to Present on the Discovery and Preclinical Development of CFT7455, a MonoDAC Degrader Targeting IKZF1/3, at the American Association for Cancer Research (AACR) Annual Meeting [Mar-10-21 04:41PM] C4 Therapeutics Reports Recent Business Highlights and Full Year 2020 Financial Results [Mar-11-21 04:01PM]